Literature DB >> 24251787

Development and evaluation of the REACH (recognise end of life and care holistically) out in dementia toolkit.

Jan M Potter1, Ramesh Fernando, Nancy Humpel.   

Abstract

AIM: To identify evidence based signs and symptoms indicative of end stage dementia, and develop the REACH toolkit as an aid for staff to consider a palliative approach.
METHOD: A systematic literature review was conducted of policy, position documents, guidelines and publications from 1988 to 2011. Inclusion criteria were any report or article identifying the signs and symptoms of end stage dementia which were associated with increased mortality and morbidity.
RESULTS: Eight signs and symptoms associated with worsening function and increased mortality were identified. These were incorporated into a toolkit. Experienced clinicians reviewed the toolkit. It was then trialled in six aged care facilities (ACFs) and as a result of the trial 182 residents with dementia were identified as being at the end stage.
CONCLUSIONS: Use of the toolkit improved the recognition of end stage dementia among staff in ACFs.
© 2013 ACOTA.

Entities:  

Keywords:  ACFs; end stage dementia; palliative care; review

Mesh:

Year:  2013        PMID: 24251787     DOI: 10.1111/ajag.12062

Source DB:  PubMed          Journal:  Australas J Ageing        ISSN: 1440-6381            Impact factor:   2.111


  2 in total

1.  Community-based palliative care is associated with reduced emergency department use by people with dementia in their last year of life: A retrospective cohort study.

Authors:  Lorna Rosenwax; Katrina Spilsbury; Glenn Arendts; Bev McNamara; James Semmens
Journal:  Palliat Med       Date:  2015-03-17       Impact factor: 4.762

2.  Context, mechanisms and outcomes in end of life care for people with advanced dementia.

Authors:  Nuriye Kupeli; Gerard Leavey; Kirsten Moore; Jane Harrington; Kathryn Lord; Michael King; Irwin Nazareth; Elizabeth L Sampson; Louise Jones
Journal:  BMC Palliat Care       Date:  2016-03-10       Impact factor: 3.234

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.